Sisunatovir

Sisunatovir
Clinical data
Other names	PF-07923568, RV521
Identifiers
	IUPAC name 1'-[[5-(aminomethyl)-1-(4,4,4-trifluorobutyl)benzimidazol-2-yl]methyl]-6'-fluorospiro[cyclopropane-1,3'-indole]-2'-one;
CAS Number	1903763-82-5;
PubChem CID	132016492;
UNII	KE63TTO7WK;
KEGG	D12200;
ChEMBL	ChEMBL4297497;
Chemical and physical data
Formula	C23H22F4N4O
Molar mass	446.450 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1CC12C3=C(C=C(C=C3)F)N(C2=O)CC4=NC5=C(N4CCCC(F)(F)F)C=CC(=C5)CN;
	InChI InChI=InChI=1S/C23H22F4N4O/c24-15-3-4-16-19(11-15)31(21(32)22(16)7-8-22)13-20-29-17-10-14(12-28)2-5-18(17)30(20)9-1-6-23(25,26)27/h2-5,10-11H,1,6-9,12-13,28H2; Key:JOPCJJSYRPUEDS-UHFFFAOYSA-N;

Sisunatovir is an investigational new drug that is being evaluated for the treatment of respiratory syncytial virus (RSV) infections.^[1] It functions as an orally administered RSV fusion inhibitor, targeting the RSV-F protein on the viral surface to prevent viral replication.^[2] Sisunatovir has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) due to its potential to address serious RSV infections, which can lead to severe respiratory conditions such as bronchiolitis and pneumonia.^[3]

References

^ "Sisunatovir - ReViral". AdisInsight. Springer Nature Switzerland AG.
^ Cockerill GS, Angell RM, Bedernjak A, Chuckowree I, Fraser I, Gascon-Simorte J, et al. (April 2021). "Discovery of Sisunatovir (RV521), an Inhibitor of Respiratory Syncytial Virus Fusion". Journal of Medicinal Chemistry. 64 (7): 3658–3676. doi:10.1021/acs.jmedchem.0c01882. PMID 33729773.
^ Park B (6 August 2020). "Sisunatovir Fast-Tracked for Serious RSV Infection". Medical Professionals Network. Haymarket Media, Inc.

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.